Study design
This was a phase 2a, investigator-initiated, randomized, placebo-controlled, double-blinded international multicenter trial enrolling at six sites in Denmark (Aalborg, Aarhus, Gødstrup, Hvidovre, Odense and Rigshospitalet); one site in Oslo, Norway; and one site in Melbourne, Australia (EudraCT: 